Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

U.S. Food and Drug Administration Approves Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1 In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy significantly improved event-free survival and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 7, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC
The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma
Neoadjuvant chemotherapy in the high-risk population demonstrated favorable pathologic responses, and was well tolerated.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 24, 2022 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
Rate of event - free survival higher with neoadjuvant pembrolizumab plus chemo versus chemo alone for early triple - negative breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 10, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
THURSDAY, Feb. 10, 2022 -- For patients with previously untreated stage II or III triple-negative breast cancer, the rate of event-free survival is higher for those receiving neoadjuvant pembrolizumab combined with chemotherapy versus neoadjuvant... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 10, 2022 Category: Pharmaceuticals Source Type: news

Prehabilitation Exercise Intervention Studied in Esophageal Cancer
Structured prehabilitation exercise during neoadjuvant chemotherapy and surgery may enhance treatment response (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 2, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news

Prehabilitation Exercise Intervention Studied in Esophageal Cancer
WEDNESDAY, Feb. 2, 2022 -- For patients with esophageal cancer, a structured prehabilitation exercise intervention during neoadjuvant chemotherapy and surgery may enhance tumor regression and downstaging in response to treatment, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 2, 2022 Category: Pharmaceuticals Source Type: news

Surprise Finding: Prehabilitation Exercise Shrinks Tumor Surprise Finding: Prehabilitation Exercise Shrinks Tumor
Patients with esophageal cancer who followed a structured exercise program during neoadjuvant chemotherapy showed significant tumor shrinkage.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer
In patients with HER2-overexpressing esophageal cancer, adding trastuzumab to neoadjuvant chemoradiation was not effective in a phase 3 trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 28, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

What's the Best Treatment Modality for Resectable Stomach Cancer? What's the Best Treatment Modality for Resectable Stomach Cancer?
For resectable gastric cancer, neoadjuvant chemoradiation may be better than other treatment modalities for achieving pathologic complete response, according to a new analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 29, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Timing Is Crucial: Sooner Is Better for Rectal Cancer Surgery Timing Is Crucial: Sooner Is Better for Rectal Cancer Surgery
Survival outcomes are considerably better for patients with rectal cancer who have surgery within 8 weeks or less after not responding to neoadjuvant chemoradiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 7, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021. The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium. “Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Rodriguez, Symposium c...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

BrighTNess Follow-Up Data Shed Light on TNBC Therapy BrighTNess Follow-Up Data Shed Light on TNBC Therapy
Patients with triple negative breast cancer had improved event-free survival when carboplatin (but not the PARP inhibitor veliparib) was added to standard neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news